WARF: P96061US

  • Assigned to WARF as biological material.

Method to Screen for Novel Antibiotics


Bernard Weisblum, Robert Giannattasio, Arcady Grenader, Andrew Ulijasz, David Kovalic

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in a new indicator strain of bacteria that may be useful in the discovery of new antibiotic compounds.
OVERVIEWThe antibiotic vancomycin targets the peptidoglycan-containing bacterial cell wall. Inducible resistance to vancomycin and other glycopeptide antibiotics is becoming a serious health problem, necessitating the development of new antibiotic compounds.
THE INVENTIONUW-Madison researchers have developed an indicator strain of Bacillus subtilis, which can detect potential antibiotic compounds that inhibit cell wall biosynthesis. This reporter strain includes the vancomycin-inducible VanA operon, which is responsible for a major form of inducible resistance to glycopeptide antibiotics, operably linked to a reporter gene.

To screen compounds for efficacy as antibiotics, a test compound is exposed to the strain. The effects of the compound on the indicator strain’s growth, as well as the presence or absence of the reporter gene product are observed. If the reporter gene product is present and growth of the indicator bacterial strain is inhibited or reduced, then the compound likely inhibits bacterial wall synthesis and is a potential, new antibiotic compound.
  • Discovery of new antibiotics
  • May help detect new antibiotics belonging to the class of peptidoglycan synthesis inhibitors
  • Useful in screening for compounds that either inhibit VanA-induced vancomycin resistance or fail to activate this resistance mechanism
  • Indicator strain is non-pathogenic, minimizing exposure of laboratory personnel to dangerous organisms
  • Can help identify potentially useful therapeutics with minimal need for expensive chemical analysis, characterization, and fermentation
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.